Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis - Cadavid, Diego; Jurgensen, Stephanie; Lee, Sophia (PloS one, 2013)
Keywords: Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Autoimmune diseases; Brain; Care and treatment; Clinical trials; Disability; Dosage and administration; Feet; Female; Humans; Immunotherapy; Impact analysis; Inflammation; Interferon; Interferon beta-1a; Interferon-beta - therapeutic use; Male; Medicine; Middle Aged; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis, Chronic Progressive - drug therapy; Multiple Sclerosis, Chronic Progressive - physiopathology; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - physiopathology; Natalizumab; Neurology; Patient outcomes; Quality of life; Retrospective Studies; Reviews; Studies; Treatment Outcome; Walking; United States; United States--US; Massachusetts